The proven leader in regulated digital health solutions: BrightInsight

BrightInsight accelerates time to market for its customers’ digital health products, including apps, healthcare provider interfaces, analytics dashboards, algorithms, medical devices, connected combination products, diagnostics and Software as a Medical Device (SaMD) across therapeutic areas. BrightInsight replaces the need for lengthy and complicated ‘build from scratch’ implementations and instead offers a pre-built and proven digital health platform designed under a Quality Management System to support global security, privacy, and regulatory requirements. Top 20 biopharma companies trust BrightInsight to build and launch their commercial regulated digital health solutions. BrightInsight is an expert at building and maintaining biopharma and medtech regulated digital health products, with multiple commercial launches in the last year alone.

The company has vast experience launching high-risk Class C Software as a Medical Device (SaMD), dosing algorithms, patient support and engagement apps, chronic disease management platforms, connected combination products, diagnostics, and more. BrightInsight’s tested technology is used by patients and providers at leading healthcare systems. BrightInsight has experience supporting regulated products across therapy areas including diabetes, respiratory, oncology, ophthalmology, obesity, hematology, immunology, neurology, and more.

Regulated Digital Health Solutions

Cardiovascular diseases affect almost half of all adults in the United States and are the leading cause of death globally. And while providers are adept at treating conditions like heart failure, hypertension and arrhythmias, effective disease management is far from guaranteed. Connected devices and cloud-based digital solutions can play an important role in helping providers better care for patients with cardiovascular conditions. While many cardiovascular patients may already be using devices like smart blood pressure cuffs, ECG monitors or smart scales, the captured data is often siloed within a device-specific ecosystem, making it difficult for providers to get a holistic view of a patient’s symptoms. When adherence slips, care tends to be reactive instead of proactive. That means patients end up in the emergency department more frequently, adversely affecting their quality of life and costing patients and payers a lot of money. Managing cardiovascular conditions doesn’t just happen in the doctor’s office. Most patients are taking daily medications, engaging in regular monitoring and pursuing lifestyle changes. But, providers rarely get updates on a patient’s progress until they come for a visit.

Digital solutions allow patients to self-report symptoms anytime, anywhere–not just during regular office visits. When this data is paired with lab work and delivered right into the EHR, providers have a better picture of a patient’s well-being. Connected medical devices such as blood pressure cuffs, weight scales and pulse oximeters can provide a more holistic view of a patient’s health…if the data is integrated. With device data displayed on a singular provider dashboard, the care team can proactively track disease progression and the effectiveness of interventions. In cardiovascular diseases, adverse events can happen quickly and sometimes unexpectedly. When connected devices alert providers to symptoms that could indicate an impending adverse event, they can reach out to the patient immediately to provide proactive care.

Solutions for Diabetes

More than 400 million people worldwide have diabetes. Devices like insulin pens, continuous glucose monitors and insulin pumps are crucial to avoid hospital visits, but they don’t provide the comprehensive support many diabetes patients need to manage their condition. Diabetes patients’ health is dependent on careful tracking of glucose levels, and this can represent a significant challenge for patients. Nearly half of patients with diabetes do not achieve adequate glycemic control. Poor medication adherence is a key factor leading to higher-than-necessary rates of morbidity and mortality. Even when patients use digital devices, they often have to manually document their blood glucose data to share with their doctors, who are juggling disparate data sources across their patient population.

BrightInsight’s Clinician Portal application allows communication and collaboration between patients and their providers, and can improve care with real-time data sharing. BrightInsight’s Patient App supports patients in their diabetes management, guiding them through connected device set-up, monitoring glucose levels, updating insulin dosage, and more.

Meet the leader behind the success of BrightInsight

Kal Patel, MD has over 20 years of experience in pharma, medtech and regulated digital health. He currently serves as Co-founder and CEO at BrightInsight, the leading global platform for biopharma and medtech regulated digital health solutions. BrightInsight has raised $166M in financing from world-renowned venture capital firms including General Catalyst, Insight Partners, New Leaf Venture Partners, and Eclipse Ventures, and attracted some of the world’s top biopharma and medtech companies as customers including Sanofi, Novo Nordisk, Roche, AstraZeneca, UCB and CSL Behring, among others. Prior to founding BrightInsight he was Chief Commercial Officer for Doctor on Demand, now one of the nation’s largest video-medicine providers, with backing from Andreessen Horowitz, Venrock, Google Ventures, and Qualcomm.

Kal founded and built Amgen’s Digital Health business unit where he had end-to-end responsibility for developing and commercializing a portfolio of regulated digital products including connected devices, Software as a Medical Device (SaMD), and algorithms. Prior to his focus on digital health at Amgen, Kal was the Global Marketing Lead for Enbrel, the company’s leading drug with over $6B in sales, where he created and launched major investments in novel clinical trials, innovative drug delivery devices, improved formulations and differentiated patient support programs. Kal started his Amgen career as Head of Corporate Strategy. Kal also spent several years at Novartis Pharmaceuticals in various sales, marketing and account leadership roles. He began his professional career at the Boston Consulting Group where he worked for a broad portfolio of Healthcare companies across the U.S. and Europe. He transferred to the company’s Budapest office as part of BCG’s prestigious Ambassador Program and was promoted early to Principal. Kal has also served as a Senior Advisor in Digital Health to the Boston Consulting Group where he helped C-level executives at pharma and medtech companies develop and execute digital health strategies.

“Our mission is to accelerate regulated digital health innovation for our biopharma and medtech customers through our scalable medical-grade platform.”